Jennifer Heng

1.2k total citations · 1 hit paper
12 papers, 825 citations indexed

About

Jennifer Heng is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Jennifer Heng has authored 12 papers receiving a total of 825 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 6 papers in Cancer Research and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Jennifer Heng's work include Lung Cancer Treatments and Mutations (11 papers), Cancer Genomics and Diagnostics (6 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Jennifer Heng is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Cancer Genomics and Diagnostics (6 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Jennifer Heng collaborates with scholars based in United States, Australia and Germany. Jennifer Heng's co-authors include Geoffrey R. Oxnard, Pasi A. Jänne, Suzanne E. Dahlberg, Lynette M. Sholl, David M. Jackman, Priyanka Shivdasani, Peter S. Hammerman, James G. Christensen, Mark M. Awad and Suman Verma and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Jennifer Heng

11 papers receiving 813 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

2016 493 citations Mark M. Awad, Geoffrey R. Oxnard et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Jennifer Heng

Since Specialization

Citations

This map shows the geographic impact of Jennifer Heng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Heng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Heng more than expected).

Fields of papers citing papers by Jennifer Heng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Heng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Heng. The network helps show where Jennifer Heng may publish in the future.

Co-authorship network of co-authors of Jennifer Heng

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Heng. A scholar is included among the top collaborators of Jennifer Heng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Heng. Jennifer Heng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	A study evaluating the different treatment modalities for EGFR mutation positive advanced NSCLC patients that acquire c-MET amplification after EGFR TKI therapy resistant 2019 ·Annals of Oncology ·Jingjing Qu, (unknown), Jennifer Heng, Cong Zhou, Yi Xiong, Wei Jiang, Na Yang	1
2	Exendin-4 Improves Yield and Function of Isolated Pre- Weaned Porcine Islets 2018 ·(unknown), Hien Lau, (unknown), Sarah Lee, Jennifer Heng, Kevin Zhang, Michael P. Alexander	8
3	Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients 2017 ·Clinical Cancer Research ·Yuebi Hu, Ryan S. Alden, Justin I. Odegaard, Stephen R. Fairclough, (unknown), Jennifer Heng, Nora Feeney, Rebecca J. Nagy, (unknown), Bryan C. Ulrich, (unknown), Richard B. Lanman, Judy E. Garber, Cloud P. Paweletz, Geoffrey R. Oxnard	63
4	OA 06.02 Final Report of the INHERIT EGFR Study - 33 Unrelated Kindreds Carrying Germline EGFR Mutations 2017 ·Journal of Thoracic Oncology ·Geoffrey R. Oxnard, Jennifer Heng, (unknown), (unknown), Kate Shane-Carson, (unknown), Georgia L. Wiesner, Judy E. Garber	8
5	MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression breakdown → 2016 ·Journal of Clinical Oncology ·Mark M. Awad, Geoffrey R. Oxnard, David M. Jackman, (unknown), (unknown), Priyanka Shivdasani, Jennifer Heng, Suzanne E. Dahlberg, Pasi A. Jänne, Suman Verma, James G. Christensen, Peter S. Hammerman, Lynette M. Sholl	493
6	Clinical Implications of Variant ALK FISH Rearrangement Patterns 2015 ·Journal of Thoracic Oncology ·(unknown), Lynette M. Sholl, Mizuki Nishino, Jennifer Heng, Pasi A. Jänne, Geoffrey R. Oxnard	41
7	Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung Cancer 2015 ·JAMA Oncology ·Adrian G. Sacher, Suzanne E. Dahlberg, Jennifer Heng, Stacy L. Mach, Pasi A. Jänne, Geoffrey R. Oxnard	189
8	Initial results of a prospective, multicenter trial to study inherited lung cancer risk associated with germline EGFR T790M: INHERIT EGFR. 2015 ·Journal of Clinical Oncology ·Geoffrey R. Oxnard, Jennifer Heng, (unknown), Irene Rainville, (unknown), Kate Shane-Carson, David P. Carbone, Georgia L. Wiesner, Judy E. Garber	2
9	The spectrum of genomic alterations in young adult non-small cell lung cancer (NSCLC). 2013 ·Journal of Clinical Oncology ·Geoffrey R. Oxnard, Jennifer Heng, Stacy L. Mach, Peter Lo, Mohit Butaney, David M. Jackman, Pasi A. Jänne	0
10	Abstract 2417: The INHERIT EGFR study: Investigating hereditary risk from T790M. 2013 ·Cancer Research ·Geoffrey R. Oxnard, (unknown), (unknown), Irene Rainville, Suzanne E. Dahlberg, Jennifer Heng, David M. Jackman, Pasi A. Jänne, Judy E. Garber	2
11	Pulsed dosing of erlotinib for central nervous system (CNS) progression in EGFR-mutant non-small cell lung cancer (NSCLC). 2013 ·Journal of Clinical Oncology ·David M. Jackman, Stacy L. Mach, Jennifer Heng, Michael S. Rabin, David A. Barbie, Leena Gandhi, Judith Marcoux, Daniel B. Costa	17
12	Investigating hereditary risk from T790M (inherit): A prospective multicentered study of risk associated with germ-line EGFR T790M. 2013 ·Journal of Clinical Oncology ·Geoffrey R. Oxnard, Jennifer Heng, Irene Rainville, Suzanne E. Dahlberg, (unknown), Georgia L. Wiesner, (unknown), David M. Jackman, Pasi A. Jänne, Judy E. Garber	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact